Immune Netw.  2011 Dec;11(6):383-389. 10.4110/in.2011.11.6.383.

Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell

• Oh SJ
• Ryu CK
• Baek SY
• Lee H

• KMID: 2150724
• DOI: http://doi.org/10.4110/in.2011.11.6.383

Abstract

BACKGROUND
EY-6 is one of the newly synthesized indoledione derivatives to induce tumor cell-specific cell death. In this study, we investigated the mechanism of immunological death induced by EY-6 at mouse colon cancer cell as well as at the normal immune cell represented by dendritic cell.
METHODS
C57BL/6 mouse syngeneic colon cancer cell MC38 was treated with EY-6, and analyzed by MTT for viability test, flow cytometry for confirming surface expressing molecules and ELISA for detection of cytokine secretion. Normal myeloid-dendritic cell (DC) was ex vivo cultured from bone marrow hematopoietic stem cells of C57BL/6 mice with GM-CSF and IL-4 to analyze the DC uptake of dead tumor cells and to observe the effect of EY-6 on the normal DC.
RESULTS
EY-6 killed the MC38 tumor cells in a dose dependent manner (25, 50 and 100 microM) with carleticulin induction. And EY-6 induced the secretion of IFN-gamma but not of TNF-alpha from the MC38 tumor cells. EY-6 did not kill the ex-vivo cultured DCs at the dose killing tumor cells and did slightly but not significantly induced the DC maturation. The OVA-specific cross-presentation ability of DC was not induced by chemical treatment (both MHC II and MHC I-restricted antigen presentation).
CONCLUSION
Data indicate that the EY-6 induced tumor cell specific and immunological cell death by modulation of tumor cell phenotype and cytokine secretion favoring induction of specific immunity eliminating tumor cells.

Keyword

Indoledione derivatives; Carleticulin; Immunological death of tumor cell; Dendritic cell

MeSH Terms

Animals
Bone Marrow
Cell Death
Colonic Neoplasms
Cross-Priming
Dendritic Cells
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Granulocyte-Macrophage Colony-Stimulating Factor
Hematopoietic Stem Cells
Homicide
Interleukin-4
Mice
Phenotype
Tumor Necrosis Factor-alpha
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4
Tumor Necrosis Factor-alpha

Figure

• 

  Figure 1 EY-6 induced tumor-specific killing. MC38 cell (A) or cultured BM-DC (B) was treated with different doses of EY-6 (25, 50 and 100 µM) for 48 hr at 37℃. At the end of the incubation, supernatants were removed and MTT solution was added to analyze the cell death. Asterisks indicate the statistical significance at p<0.05.

• 

  Figure 2 Surface expression of immunogenicity-inducing molecules on the tumor cells killed by EY-6. MC38 cells were overnight incubated with or without EY-6 25 µM at 37℃. Then cells were stained with FITC or PE-tagged antibodies against surface molecules as was described in the "Materials and Methods" section.

• 

  Figure 3 Increased DC uptake of EY-6 treated MC38 cells. MC38 cells were overnight incubated with or without EY-6 25 µM at 37℃, then stained with CRT-FITC. Cultured-DC was stained with CD11c-PE. Two cells were co-incubated for 6 hr at 37℃ before observe the proportion of tumor cell uptake DCs by measuring CD11c+CRT+ double positive cells.

• 

  Figure 4 Cytokine secretion from the EY-6 treated MC 38 cells. MC38 cells were treated with EY-6 25 µM at 37℃. At several incubation time points, supernatants were obtained to measure the secreted cytokines (IFN-γ or TNF-α) by ELISA following manufacturer's protocol. Asterisks indicate the statistical significance at p<0.05.

• 

  Figure 5 Effect of EY-6 on the DC maturation. Cultured BM-DC by the methods described in the "Materials and Methods" section, was treated with 25 µM EY-6 for 18~24 hr at 37℃. At the end of the incubation, harvested and stained the cells with FITC or PE-tagged antibodies for the surface molecules to identify DCs.

• 

  Figure 6 Effect of EY-6 on the DC for the OVA-specific cross presentation to CD4+(MHC II) and CD8+(MHC I) T cells. Cultured BM-DC was treated with EY-6 25 µM for overnight, then introduced with OVA before start the co-culture with MHC-restricted and OVA-specific T cell hybridomas. Details of methods are described in the "Materials and Methods" section. (A) IL-2 (pg/ml) secretion from the MHCII-restricted DOBW cells were measured by ELISA. (B) Color change induced by lacZ activity in the MHC I-restricted B3Z cells was measured. Numbers in Y-axes represent the absorption at OD580 nM. None of the responses were statistically significant.

Reference

1. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 2007. 67:7941–7944.

2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006. 313:1960–1964.

3. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008. 14:141–151.

4. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008. 8:59–73.

5. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother. 2000. 49:181–185.

6. Spreafico F, Vecchi A, Colotta F, Montovani A. Cancer chemotherapeutics as immunomodulators. Springer Semin Immunopathol. 1985. 8:361–374.

7. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982. 155:1063–1074.

8. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002. 62:2353–2358.

9. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005. 11:6713–6721.

10. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001. 61:3689–3697.

11. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010. 16:3100–3104.

12. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009. 28:578–590.

13. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007. 13:54–61.

14. Ko JH, Yeon SW, Ryu JS, Kim TY, Song EH, You HJ, Park RE, Ryu CK. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg Med Chem Lett. 2006. 16:6001–6005.

15. Chung KH, Hong SY, You HJ, Park RE, Ryu CK. Synthesis and biological evaluation of 5-arylamino-1H-benzo[d]imidazole-4,7-diones as inhibitor of endothelial cell proliferation. Bioorg Med Chem. 2006. 14:5795–5801.

16. Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY. Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem. 2007. 15:451–457.

17. Seo JM, Jin YR, Ryu CK, Kim TJ, Han XH, Hong JT, Yoo HS, Lee CK, Yun YP. JM91, a newly synthesized indoledione derivative, inhibits rat aortic vascular smooth muscle cells proliferation and cell cycle progression through inhibition of ERK1/2 and Akt activations. Biochem Pharmacol. 2008. 75:1331–1340.

18. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res. 1991. 51:1185–1189.

19. Janelidze S, Bexell D, Badn W, Darabi A, Smith KE, Fritzell S, Gunnarsson S, Milos P, Bengzon J, Salford LG, Siesjö P, Visse E. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas. J Immunother. 2009. 32:593–601.